T cells bearing chimeric antigen receptors (CARs) are broadly categorised into first-and second-generation receptors. Second-generation CARs contain a co-stimulatory signalling molecule and have been shown to secrete IL-2, undergo greater proliferation and to have enhanced persistence in vivo. However, we have shown that T cells bearing a first-generation CAR containing a CD19-targeting scFv (single-chain variable fragment) and the CD3z-signalling domain are able to produce IL-2 upon co-culture with CD19 þ B-cell lymphomas independent of CD28 activity. Here, we report that signalling through endogenous CD2 following ligation with its ligands, CD48 in mouse and CD58 in humans, drives IL-2 production by firstgeneration CD19-specific CAR. Moreover, the high levels of IL-2 produced by human T cells engrafted with a second-generation CD28-containing CAR during target-cell recognition are dependent to a degree upon CD2 receptor activity. These observations highlight the fact that the functional activity induced by T-cell-expressed CARs is dependent upon endogenous 'natural' receptor interactions. A deeper understanding of the role of these activities will serve to further refine the design of future CARs to either exploit or avoid these interactions.
INTRODUCTION
Adoptive immunotherapy as a treatment for cancer using T cells bearing a chimeric antigen receptor (CAR) is currently under clinical investigation in several sites worldwide.
1 B-cell malignancies appear particularly amenable to this approach with significant anti-tumour efficacy seen in animal models. 2 In their simplest form, CARs consist of an scFv (single-chain variable fragment) linked to a T-cell-signalling molecule such as CD3z. 3 Upon antigen ligation, these first-generation CARs drive 'signal one'-type signalling resulting in interferon gamma (IFNg) production and target-cell cytotoxicity. However, signal one alone is thought to be sub-optimal as further co-stimulatory signals are required to drive full T-cell activation, survival and proliferation. 4, 5 To this end, second-and third-generation CARs containing the signalling domains for receptors, such as CD28, 4 --1BB and OX-40, have been produced that can compensate for the lack of co-stimulation provided by first-generation CARs. Interestingly, our previous studies using mouse T cells engrafted with a CD19-specific CD3z first-generation CAR produced IL-2 during co-culture with CD19 þ B-cell lymphoma target cells, 6 suggesting that these T cells were receiving co-stimulatory signals independent of the CAR, with the B-cell targets being the obvious source driving this co-stimulation effect. However, this IL-2 secretion was found to be independent of the major ligands (CD80 and CD86) for the most studied co-stimulatory receptor CD28. 6 We therefore sought to identify the molecules present on B-cell lymphoma tumour cells that were driving CAR T-cell IL-2 production and to question whether these 'natural' T-cell --target cell interactions impacted upon the activity of second-generation CAR T cells.
RESULTS AND DISCUSSION
The interaction of the mouse T-cell surface-receptor CD2 with its ligand CD48 results in an increase in IL-2 and IFNg synthesis through mRNA stabilisation. 7 Mouse T cells bearing the CD19-specific CD3z CAR (aCD19z) highly express CD2 (data not shown), whereas CD48 is also highly expressed on A20 Balb/c lymphoma cells gene-modified to express the human CD19 ligand (A20hCD19, Figure 1a) . Blockade of the CD2 --CD48 interaction between aCD19z T cells and A20hCD19 target cells by an anti-CD48 antibody significantly reduced the levels of antigen-driven secretion of IFNg (Figure 1b ) and IL-2 ( Figure 1c ). Experiments in which excess anti-CD48 was washed off the tumour cells before the addition of aCD19z T-cells confirmed that CD48 expression on tumour cells and not T cells was responsible for co-stimulation (data not shown). Transcript analysis further confirmed that the suppression in the level of cytokines also occurs at the mRNA level during the CD2 --CD48 blockade ( Figure 1d ) and that this suppression was rapid, occurring within 3 h.
To confirm the significance of the role of CD48, lentiviralmediated small hairpin RNA (shRNA) knockdown 8 of CD48 expression in A20hCD19 lymphoma cells was used to generate a clone expressing a much reduced level of CD48 (mean fluorescence intensity of CD48 staining 2.5 for CD48 lo versus 531 of A20hCD19 cells, Figure 1a) . Consequently, when cultured with CD48 lo A20hCD19 tumour cells, aCD19z CAR T cells produced significantly reduced levels of IL-2 (49% of A20hCD19 control target cells, Figure 1e ) despite equivalent levels of CD19 target expression (data not shown). These absolute levels were higher than that achieved with antibody blockade, most likely due to the remaining low level of CD48 expression on the target cells. Furthermore, experiments using purified CAR T-cell subsets confirmed that CD4 þ CAR T cells were primarily responsible for antigen-specific IL-2 production and this could be blocked by either anti-CD48 or anti-CD2 mabs (Figure 1f) . Importantly, similar results were seen in preliminary experiments using mouse T cells bearing a mouse CD19-specific CAR-targeting A20 cells, indicating that these results were not due to the targeting of a human protein expressed on a mouse cell line (data not shown). These results strongly implicate CD2 as being the major receptor driving IL-2 production in aCD19z CAR T cells when targeting B-cell lymphoma.
As second-generation CAR's incorporate co-stimulatory signalling domains to drive the production of IL-2, 9,10 we questioned whether CD2 also impacted upon IL-2 production in these more advanced CARs when targeting tumours expressing CD48. The addition of CD28 to the CD19-targeting CAR (aCD19CD28z) did not significantly increase the absolute level of IL-2 produced above that of aCD19z CAR T cells (Figure 2a) , although there was a trend to higher IL-2 production. However, in contrast to aCD19z T cells, blocking antibodies to CD48 on A20hCD19 tumour cells or CD2 on T cells had no discernible effect upon IL-2 secretion 
from CD4
þ aCD19CD28z T cells ( Figure 2b ). Moreover, blocking CD2 --CD48 ligation did not impact upon the ability of aCD19z or aCD19CD28z T cells to lyse CD19 þ tumour cells ( Figure 2c ). No lysis was seen with control non-signalling aCD19 mtm T cells.
In humans, the ligand for CD2 is CD58, which is structurally related to murine CD48 and is expressed on many haematopoietic cells including B cells. 11 Antibody blockade of CD58 present on Raji tumour cells resulted in a 60% reduction of IL-2 production by human T cells engrafted with the aCD19z CAR after tumour-CAR T-cell co-culture ( Figure 2d ). This reduction in IL-2 production was even more pronounced when CD58 was blocked on the Nalm-6 cell line (Figure 2d ) potentially due to the lack of CD80/CD86 co-stimulatory molecules expressed by this tumour line. 12 In contrast to mouse T cells, the addition of the CD28-signalling domain into the CAR induced an enhanced level of IL-2 production as compared with aCD19z T --cells, which could be partially reduced through CD58 blockade (Figure 2e ). To extend these observations, aCD19z and aCD19CD28z CAR T cells from five donors were co-cultured with Raji or Nalm-6 cell lines in the presence of anti-CD58 or isotype control antibodies. CD58 blockade induced a significant reduction in the frequency of CD4 þ IL-2 þ CAR T cells when cultured with both cell lines irrespective of whether the CD28 domain was present (Figures 3a and b) . Although the absolute frequency of CD8 þ IL-2 þ CAR T cells was much lower, the relative frequency of these cells was reduced in aCD19z and aCD19CD28z CAR T-cell populations when CD58 was blocked, which reached statistical significance in the Nalm-6 cultures (Figures 3c and d) . Thus, the high levels of IL-2 produced as a result of aCD19CD28z CAR activity in human T cells appears to incorporate a contribution from CD2 --CD58 interactions when targeting CD58 þ tumour cells, whereas CD2 ligation in the mouse does not appear to significantly enhance IL-2 cytokine production induced by the same receptor. Whether this is due to downstream signalling differences in mouse against human T cells or whether there is an intrinsic difference in the way that the human receptor sequences function in mouse T cells remains unclear.
CD58 is expressed on all cell types 13 and at high levels on aggressive diffuse large B-cell lymphoma, 14 whereas it is also frequently over expressed in B-cell acute lymphoblastic leukaemia. Together these observations suggest that CAR T cells targeting these malignancies may benefit from CD2-based signalling and enhanced-IL-2 production. As most clinical CAR T-cell adoptive transfer protocols include in vivo IL-2 support, there may be a rationale to reduce the level of IL-2 given to patients where the tumour expresses CD58. On the other hand, many solid tumours, such as gastric and colorectal carcinomas, have reduced/ absent CD58 expression and may benefit from the inclusion of the CD2-signalling domain in CAR design. 16 --18 However, whereas mouse aCD19z T cells can effectively eradicate long-term systemic B-cell lymphoma in syngeneic mice, 5 these aCD19z T cells fail to persist for extended periods 11 suggesting that IL-2 induced by CAR T cells through CD2 ligation is not sufficient to support aCD19z T cells. Importantly, host B cells returned to normal frequencies shortly after aCD19z T-cell depletion in this model. 11 However, T cells bearing a CD28-containing CD19-specific CAR maintained a longer duration of B-cell depletion indicative of prolonged activity of the CAR T cells. 19 This observation suggests that CD28 signalling from a CAR may provide greater survival signals than that of endogenous CD2 signalling in vivo.
An obvious question raised by this work is why does endogenous CD28 signalling not appear to have a role in the aCD19z T-cell situation 6 although CD2 does function? Recent studies have confirmed that the CAR's containing the CD3z transmembrane domain strongly interacts with the endogenous TCR/CD3 complex 20 and these interactions may affect endogenous CD28 function. Moreover, although CD2 ligation in aCD19z CAR T cells is active in terms of cytokine production, it is not clear whether CD2 is functioning equivalently to that achieved during endogenous TCR binding of target antigen. Additionally, very little is known about the biochemical structure/cell surface location and structural interactions of receptors not using the CD3z transmembrane domain including the CD28-containing CAR used in these and other studies. Indeed, our own recent observations suggest that CARs incorporating a CD3z transmembrane domain with CD28-signalling domain have a far reduced co-stimulatory signal capacity as compared with receptors bearing the CD28 transmembrane domain (JSB, personal communication). Indeed, initial testing of a CD19-specific CAR bearing the CD2 endodomain fused to CD3z failed to drive enhanced-IL-2 production when expressed in human T cells and co-cultured with CD58 blocked Raji and Nalm-6 target cell lines (Figures 3e and f) . As such, further detailed examination of the biochemical and structural aspects of T cells bearing CARs is required in order to fully understand the relative frequency of T-cell activation mediated by the CAR and to understand the role that naturally expressed host proteins play in the anti-tumour response mediated by the CAR-expressing T-cell.
MATERIALS AND METHODS

General reagents
Hamster anti-mouse CD3e (clone145-2C11) and hamster anti-mouse CD28 (clone 37.51) were obtained from BD-Pharmingen (Cowley, UK). Human Interleukin-2 (Proleukin) was obtained from Novartis (Horsham, UK) and recombinant murine IL-7 from R&D Systems (Abingdon, UK). FITC, PE and PE-Cy5-conjugated monoclonal antibodies to human CD2, CD19, human CD34, mouse CD2, CD4, CD8, CD19 and CD48, were obtained from BD-Pharmingen. PE-conjugated anti-human CD58 was obtained from Serotech and all chemical reagents from Sigma-Aldrich (Poole, UK) unless otherwise stated. Matched antibody pairs to mouse IFNg and IL-2 were obtained from BD-Pharmingen (R4-6A2 and JES6-1A12/5H4, respectively). Matched antibody pairs to human IL-2 were obtained from R&D Systems (MAB602 and BAF202). Blocking antibody to mouse CD48 (HM48-1) and mouse IgG 1 (G235-2356) were obtained from BD-Pharmingen, blocking antibody to mouse CD2 (RM2-5) and Rat IgG 2b (eB149/10H5) from eBioscience (Hatfield, UK) and blocking antibody to human CD58 from R&D Systems (Novartis). The shRNA vectors pSicoR cherry red-luc and pScioR cherry red were a gift from Dr Taylor Jacks (Massachusetts Institute 
Cell culture
All cell culture media were obtained from Invitrogen (Paisley, Scotland) unless stated otherwise. 293T (ATCC CRL-11268) and GP þ e86 (ref. 23 ) cells were cultured in DMEM Glutamax media supplemented with 10% fetal calf serum and passaged by trypsinization. The A20/A20hCD19iGFP Balb/c B-cell lymphoma line (ATCC TIB-208) 6 and Raji (ATCC CCL-86) was grown in RPMI 1640 (BioWhittaker, Lonza, Verviers, Belgium) supplemented with 10% heat-inactivated fetal calf serum, 25 mM Hepes, 50 nM 2-mercaptoethanol and 2 mM L-glutamine, penicillin, streptomycin (complete RPMI).
Generation of CARs and producer cell lines
The pMP71tCD34.2A.CD19z and pMP71tCD34.2A.CD19 mtm retroviral vectors were generated, as described previously.
6,24 pMP71tCD34.2A.CD19CD28z retroviral vectors were generated as follows. Truncated CD28(IEV) (bp 336 --660, aa 114 --220) sequences 10 were generated by PCR, fused to human CD3z using overlapping primers and annealing PCR and sub-cloned into pMP71tCD34.2A.CD19/pMP71tCD34.2A.MFE as a NotI, HindIII fragment. PG13/GP þ e86 producer cell lines were generated as previously described. 6 The aCD19.CD2z CAR was cloned by overlapping PCR. To this end, CD2 was amplified from human complementary DNA using the following primer pair: 5 0 -GAGCTTTCCATGTAAATTTGTAGCCAGCTTCCTTCTG-3 0 and 5 0 -TTAATTAGAGGAAGGGGACAATGAGTTTTCTGCTGC-3 0 . A 471-bp fragment encoding the complete human CD2 transmembrane and cytoplasmic domain, and nine extracellular amino acids, was then amplified from this product using a 5 0 primer that included a 5 0 NotI site (5 0 -GCGGCCGCAG AGAAAGGTCTGGACATCTATCTCATCATTGGCATATGT-3 0 ), and a 3 0 reverse primer that overlapped with the cytoplasmic domain of CD2 (5 0 -CTCCTGCT GAACTTCACATTAGAGGAAGGGGACAATGAGTTTTCTGCTGCCCCATGGGG-3 0 ). CD3z was amplified from rKat.om1.B18.CD3z.IRES.GFP using a 5 0 primer that overlaps with the CD2 cytoplasmic domain (5 0 -CATTGTCCCCTTCCT AATGTGAAGTTCAGCAGGAGCGCAGACGC-3 0 ) and a 3 0 reverse primer that included a 3 0 XbaI site and stop codon (5 0 -TTTGAGTGGTGAAATCTCTAGAT TATTAGCGAGGGGGCAGGGCCTGC-3 0 ). The fragments were annealed and the correctly annealed sequence amplified using the 5 0 CD2 and 3 0 CD3 primers. The CAR was cloned into rKat.MFE23 using a NotI and blunted XbaI site. Finally, the MFE23 scFv sequence was replaced with the áCD19 scFv via a ClaI/NotI digest from the existing aCD19.CD3z CAR sequence.
Isolation, transduction and ex vivo culture of murine T cells Mouse T cells were generated as previously described. 6 Isolation, transduction and ex vivo culture of human T cells Human T cells were generated as previously described. 25 Generation of CD48 shRNA A20hCD19 cell line
We prepared CD48shRNA lentiviral vectors by cloning palindromic doublestranded oligonucleotide sequences of CD48shRNA into HpaI and XhoI sites of a pSicoR-cherry red vector following instructions from the laboratory of Dr Taylor Jacks (Massachusetts Institute of Technology). 8, 26 Lentivirus was produced by transient transfection of 293T cells in 150 mm 3 dishes by calcium chloride precipitation. 27 Vectors were added in the ratio 20 mg pSicoR, 13 mg pCMVDR8.91, 7 mg pMD2.g. Lentiviral particles were purified by ultracentrifugation at 71935 g, 4 1C, 2 h (Sorvall Ultra pro 80). A20hCD19iGFP cells were transduced with pSicoR-luciferase or pSicoR-CD48 by two rounds of spinfection at 2500 rpm for 3 h. Cells were sorted 5 --7 days later for cherry-red expression on a FACSVantage and analysed for CD48 expression by flow cytometry. Cells transduced with the shRNA vectors with the 19mer 145 (5 0 -GGACCATATAAACGTATCA-3 0 ) and 655 (5 0 -GGAGTATGTTGGACTGCAA-3 0 ) sequences were selected as giving the highest level of CD48 knockdown by flow cytometry. A20hCD19iGFP cells that went through two rounds of transduction with the CD48shRNA 655 vector and one transduction with the CD48shRNA 145 vector were sorted (FACSVantage) for CD48-negative cells and selected as the line with the lowest possible CD48 expression levels. A20hCD19iGFP pSicoRluc cells were generated by two rounds of transduction with the pSicoR cherry red-luc vector and cell sorting for cherry-red expression.
T-cell/tumour cell co-cultures A total of 10 5 tumour cells were cultured with 10 5 murine T cells (30 --40% CAR þ ) for 24 h at 37 1C in U-bottomed 96-well plates and supernatant analysed for IFNg and IL-2 by enzyme-linked immunosorbent assay. The limit of detection was 31.25 pg ml À1 . In some instances, A20hCD19 cells were pre-treated for 30 min with 10 mg ml À1 Hamster IgG 1 /anti CD48Ab that was not removed during the 24-h co-culture or mouse T cells were pre-treated for 30 min with 10 mg/ml Rat IgG 2b /anti-CD2Ab. At the end of the culture period, cells were re-suspended in phosphate-buffered saline/ 1% fetal calf serum containing anti-mouse CD19PE and incubated on ice for 30 min. 10 000 CountBright counting beads (Molecular Probes, Invitrogen, Eugene, OR, USA) were added and samples acquired on a FACscan or FacsCalibur. The number of remaining CD19 þ cells was calculated using the formula: (number of Ag-positive cell events/number of bead events) Â number of beads added. Relative cytotoxicity was determined by taking the number of tumour cells remaining in signalling-active CAR T-cell cultures divided by the number of tumour cells in the relevant aCD19 mtm CAR culture expressed as a percentage to determine relative cytolysis.
Human T-cell/tumour (Raji, Nalm-6) co-cultures were performed in a similar manner except that tumour cells were pre-treated with mouse IgG 1 /aCD58Ab where appropriate.
Intracellular flow cytometry
A total of 5 Â 10 5 tumour cells were co-cultured with 5 Â 10 5 CAR or control T cells in 1 ml of complete media supplemented with 1 ml of Golgistop (BD Biosciences, Oxford, UK) per well of a 24-well plate. After 16 h, cells were collected, blocked with Fc blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) and stained with CD4-FITC and CD34-Pe-Cy5 mabs (BD Biosciences) for 20 min. After washing, intracellular staining was performed using Cytofix/Cytoperm kit (as directed by the manufacturer's instructions) using anti-IFNg and anti-IL-2 (BD Biosciences). Samples were analysed using a BD FACs Calliber and FlowJo (Treestar, Ashland, OR, USA) software. In order to identify cytokine-producing T cells, lymphocytes were gated on a FSC-H v SSC-H plot, CAR T cells identified by CD34 expression and cytokine-producing cells identified by comparison with T cells cultured in the absence of target cells.
Real-time PCR
A total of 5 Â 10 5 A20hCD19iGFP tumour cells were co-cultured with 5 Â 10 5 aCD19z murine T cells (38% CAR þ ) in 24-well plates for 3 or 24 h in the presence of 10 mg ml À1 Hamster IgG 1 or anti-CD48Ab. CAR þ T cells were purified using CD34 microbeads (Miltenyi Biotech) and RNA isolated using the QIAGEN RNeasy kit as per the manufacturer's instructions (Qiagen, Crawley, UK) and up to 1 mg of total RNA used to synthesize complementary DNA using the Superscipt III first-strand complementary DNA synthesis kit (Invitrogen). Real-time PCR for mouse IL-2 was performed on an ABI 7900 Prism Instrument using the mouse IL-2 or mouse b-actin TaqMan Gene Expression Assays (Applied Biosystems, Warrington, UK) as per the manufacturer's instructions.
